Table 1.
Application of EVs as therapeutic delivery tools for cancer treatments.
| Type of EVs | Therapeutic cargo | EV source | target tissue/cell | Outcome | Reference |
|---|---|---|---|---|---|
| MVs | mRNA and/or protein | HEK293T | schwannoma tumor | Effectively inhibit schwannoma tumor growth in vitro and in vivo | Mizrak72 |
| exosomes | let-7a miRNA | HEK293T | breast tumors | Tumor been restrained observably | Ohno73 |
| MVs | transforming growth factor β1(TGF-β1) siRNA | mouse fibroblast L929 cell | murine sarcomas | Significantly inhibited TGF-β1 expression and suppressed primary tumor growth | Zhang74 |
| exosomes | miR-146b | MSC | glioma | Significantly reduced glioma xenograft growth in a rat model of primary brain tumor | Katakowski75 |
| exosomes | miR-9 | MSC | glioblastoma multiforme | Showed a potential role for MSCs in the functional delivery of synthetic anti-miR-9 to reverse the chemoresistance of GBM cells | Munoz76 |
| exosomes | doxorubicin | immature mouse dendritic cells | breast cancer | Caused less cardiac damage, and more effectively in inhibition of tumor growth | Tian79 |
| MVs | methotrexate (MTX) and cisplatin | H22 hepatoma cells | hepatocarcinoma | Inhibited the growth of subcutaneous hepatocarcinoma | Tang81 |
| exosomes | poly and cyclophosphamide | DCs | L1210 tumour | Have a great capacity to resist tumor growth, increase survival time of mouse and stimulates DCs maturation | Guo83 |
| MVs | paclitaxel | MSCs | pancreatic tumors | Effectively suppressed pancreatic tumors | Pascucci84 |
| exosomes | tumor antigens | TS/A cells | breast cancer | induce potent CD8+ T-cell-dependent antitumor effects | Wolfers85 |
| exosomes | CagA | CagA- expressing cells | gastric epithelial cells | Delivering the CagA to gastric epithelial cells | Shimoda86 |
| exosomes | Survivin | melanoma | pancreatic carcinoma cells | Induced a significant increase in apoptotic cell death | Aspe87 |